Industry leaders gather in Sonoma, California, for Newsweek's AI Impact Summit. Follow Newsweek's live blog for updates.

TV18, Surya Gummadi, President of Americas at Cognizant, and Babak Hodjat, the company’s CTO of AI, explained how their ...

On some negative news about one of its investigational programs, the stock of pharmaceutical company Gilead Sciences (NASDAQ: GILD) took some hits on Tuesday. Investors traded it down by more than ...

At ASCO, Gilead’s cell therapy unit Kite Pharma reported some early positive data for its anti-CD19/CD20 bicistronic CAR-T therapy in advanced B-cell lymphoma. Another bivalent CAR-T candidate ...

Emily, who had been operating undercover in Gilead, returns to assist in the rebellion. Her contributions bolster the resistance's efforts, and she reunites with June, reinforcing their shared ...

View the latest Eventide Gilead Fund;N (ETGLX) stock price, news, historical charts, analyst ratings and financial information from WSJ.

On June 4, Jefferies analyst Michael Yee reaffirmed a Buy rating on Gilead Sciences Inc. (NASDAQ:GILD), maintaining his price target at $130.

Gilead Sciences, Inc. (NASDAQ:GILD) is not on our list of 30 Most Popular Stocks Among Hedge Funds.As per our database, 79 hedge fund portfolios held Gilead Sciences, Inc. (NASDAQ:GILD) at the end ...

Headquartered in Teaneck, NJ, Cognizant Technology Solutions Corporation is a leading professional services company. The company was spun off from Dun & Bradstreet in 1996 and went public in 1998.